Generic Imitrex Availability

See also: Generic Imitrex Statdose

Imitrex is a brand name of sumatriptan, approved by the FDA in the following formulation(s):

IMITREX (sumatriptan succinate - injectable; subcutaneous)

  • Manufacturer: GLAXOSMITHKLINE
    Approval date: December 28, 1992
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [RLD] [AP]

IMITREX (sumatriptan succinate - tablet; oral)

  • Manufacturer: GLAXOSMITHKLINE
    Approval date: June 1, 1995
    Strength(s): EQ 100MG BASE [RLD] [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]

Has a generic version of Imitrex been approved?

Yes. The following products are equivalent to Imitrex:

sumatriptan succinate injectable; subcutaneous

  • Manufacturer: BEDFORD
    Approval date: February 6, 2009
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]
  • Manufacturer: FRESENIUS KABI USA
    Approval date: March 2, 2009
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]
  • Manufacturer: FRESENIUS KABI USA
    Approval date: September 18, 2009
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]
  • Manufacturer: INJECTALIA
    Approval date: August 11, 2010
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]
  • Manufacturer: JHP PHARMS
    Approval date: July 9, 2009
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]
  • Manufacturer: PAR PHARM
    Approval date: October 9, 2009
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]
  • Manufacturer: SAGENT AGILA
    Approval date: July 28, 2010
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]
  • Manufacturer: SAGENT STRIDES
    Approval date: June 10, 2010
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]
  • Manufacturer: SANDOZ
    Approval date: February 6, 2009
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]
  • Manufacturer: TEVA PHARMS USA
    Approval date: February 6, 2009
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]
  • Manufacturer: WOCKHARDT
    Approval date: February 6, 2009
    Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) [AP]

sumatriptan succinate tablet; oral

  • Manufacturer: APOTEX INC
    Approval date: June 19, 2012
    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]
  • Manufacturer: AUROBINDO PHARMA
    Approval date: August 10, 2009
    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]
  • Manufacturer: DR REDDYS LABS INC
    Approval date: August 10, 2009
    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]
  • Manufacturer: MYLAN
    Approval date: August 10, 2009
    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]
  • Manufacturer: MYLAN
    Approval date: November 2, 2009
    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]
  • Manufacturer: ORCHID HLTHCARE
    Approval date: August 10, 2009
    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]
  • Manufacturer: RANBAXY
    Approval date: February 9, 2009
    Strength(s): EQ 100MG BASE [AB]
  • Manufacturer: RANBAXY
    Approval date: August 10, 2009
    Strength(s): EQ 25MG BASE [AB], EQ 50MG BASE [AB]
  • Manufacturer: SANDOZ
    Approval date: August 10, 2009
    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]
  • Manufacturer: SUN PHARM INDS
    Approval date: August 10, 2009
    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]
  • Manufacturer: TEVA
    Approval date: February 9, 2009
    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]
  • Manufacturer: WATSON LABS
    Approval date: August 10, 2009
    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Imitrex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Imitrex.

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.
Advertisement
Close

Recommended

(web4)